MSPharma: Lucentis Biosimilar Receives Marketing Authorization from the Saudi Food & Drug Authority
Formycon AG and MS Pharma announced that Ravegza (FYB201), a biosimilar to Lucentis (ranibizumab), has received marketing authorization from the
Read full article »
MS Pharma is a pharmaceutical company that engages in developing, manufacturing and marketing generic prescription medicines.
Read more